drugset
drugset / Trial / NCT05089123

The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old

NCT05089123 ↗

Phase 3 Completed 320 enrolled St. Petersburg Research Institute of Vaccines and Sera
RandomizedParallel-groupDouble-blindPrevention

Summary

This trial by its design was a prospective, multicenter, double blind, randomized comparative clinical trial of the IIIb-IV phase which was carried out in parallel groups of volunteers over the age of 60

Timeline

Start
2020-03-03
Primary completion
2020-05-28
Completion
2020-08-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Flu-M Vaccine 0.5 ml Intramuscular
Comparator Inactivated Split Influenza Vaccine Vaccine 0.5 ml Intramuscular

Indications

influenza